{"name":"Vascular Biogenics Ltd. operating as VBL Therapeutics","slug":"vascular-biogenics-ltd-operating-as-vbl-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"VB-111 + Paclitaxel","genericName":"VB-111 + Paclitaxel","slug":"vb-111-paclitaxel","indication":"Recurrent Glioblastoma","status":"phase_3"},{"name":"VB-111 + bevacizumab","genericName":"VB-111 + bevacizumab","slug":"vb-111-bevacizumab","indication":"Glioblastoma","status":"phase_3"}]}],"pipeline":[{"name":"VB-111 + Paclitaxel","genericName":"VB-111 + Paclitaxel","slug":"vb-111-paclitaxel","phase":"phase_3","mechanism":"VB-111 is a targeted anti-vascular endothelial growth factor (VEGF) aptamer that inhibits tumor growth by blocking VEGF, while Paclitaxel is a microtubule inhibitor that disrupts cell division.","indications":["Recurrent Glioblastoma"],"catalyst":""},{"name":"VB-111 + bevacizumab","genericName":"VB-111 + bevacizumab","slug":"vb-111-bevacizumab","phase":"phase_3","mechanism":"VB-111 is a targeted therapy that works by inhibiting the expression of vascular endothelial growth factor (VEGF) mRNA, while bevacizumab is a monoclonal antibody that directly binds to VEGF.","indications":["Glioblastoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPa0JLS0dZS0RjSFowOTY5b2EweExtUkplVkhKNXZPbUhpRkxNMTlhUnlGWEY3TzJCY3B5djFhMHV5RWZ3NXh3Ty1pLWNaMTBFQXlQSnNLajNlOWZlT2pDQWdybFlPSktfQW5WMkVyLTZ2a1VhaDQ0TkhGSnN0VUZoeHNFSWNHMlVUdHNhMzNDc2lQcjlZS04wMXBWWXBXRmtwTUhuRnA0WWw1bW1GNWp4bURMdWVVU2JiWDh0MXd5dDJENGZsc0o3MFZGc3Q?oc=5","date":"2023-10-16","type":"deal","source":"GlobeNewswire","summary":"Notable Labs Closes Merger Transaction With VBL Therapeutics - GlobeNewswire","headline":"Notable Labs Closes Merger Transaction With VBL Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQcnl5UXNkTzBDeldONFNlc0NGYWxWYXNKTEtNMXpkWUJscm9Bd0dkR0IxU3BTZUNyaTFGYzB3TURQSWhYUHhuWWN0U1pVaDNSbnp0eWpOV2xfQ2NnQVpmUUg4RDhnMXZ2MG1OMFV2N2dmQTFFMnhXQ0dzYnhGLU9rcDJXcFhOc2d1VkVUbXd0SzA?oc=5","date":"2023-02-16","type":"pipeline","source":"Yahoo Finance","summary":"VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash - Yahoo Finance","headline":"VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE4wQ2ZQcnVxSVgyV3pLYy1yQ2Zvak9yeS1wak5hRE1oM2QtTzVpWDFTLUVJMENHS0tocEEtNGwzOFVVeWNlUUpiVXZHWElqdjRTMWNMMGxzZlRKRkRFRTFlR2JTUFBqWDd6SC1fcm0zaVQzUlplRlo2SXRjakRqdw?oc=5","date":"2021-12-20","type":"pipeline","source":"Moomoo","summary":"Press Release: VBL Therapeutics Selected for EUR17.5 Million of Funding from Horizon Europe EIC Accelerator Program - Moomoo","headline":"Press Release: VBL Therapeutics Selected for EUR17.5 Million of Funding from Horizon Europe EIC Accelerator Program","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2014-11-03","type":"trial","source":"GlobeNewswire","summary":"VBL Therapeutics to Present Interim Phase 2 Data From - GlobeNewswire","headline":"VBL Therapeutics to Present Interim Phase 2 Data From","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}